Nuvectis Pharma (NVCT) AI Stock Analysis

• Market Cap: $217.21M
• Dividend Yield: N/A
• Average Volume (3M): 89.48K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.65
• Revenue Growth: N/A
• EPS Growth: -16.26%
• Country: US
• Employees: 13
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.44
• Shares Outstanding: 25,614,897
• 10 Day Avg. Volume: 112,705
• 30 Day Avg. Volume: 89,483
• PEG Ratio: 0.22
• Price to Book (P/B): 9.53
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -7.56
• Enterprise Value/Market Cap: 0.84
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -7.04
• 1Y Price Target: $15.67
• Price Target Upside: 84.75% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): -1.06
• Revenue Forecast (FY): N/A

• Rating: 54 Neutral
• Price Target: $8.50 ▲(0.24% Upside)

The score is primarily held back by weak financial performance (no revenue, widening losses, and continued cash burn), partially offset by a low-risk capital structure (no debt) and improving equity. Technicals are a meaningful positive with an uptrend versus key moving averages and supportive momentum, while valuation remains only neutral due to loss-driven negative P/E and no dividend support.

Positive Factors

Low Financial Leverage

No debt materially reduces bankruptcy and interest-rate risk and gives management durable financial flexibility to prioritize R&D cadence. Over 2–6 months this lowers fixed-cost burdens, preserving optionality to fund trials via equity or partnerships without servicing debt.

Improving Equity Base

A stronger equity position improves capitalization and extends runway versus prior years, enabling the company to absorb ongoing R&D losses longer. This durable improvement supports partner negotiations, licensing flexibility, and reduces immediate financing pressure over the medium term.

Targeted Oncology Pipeline

Focusing on genetically defined cancers and specific mechanisms (HSF1 pathway, SRC/YES1 kinases) provides structural advantages: clearer patient selection, potentially higher trial success rates, and stronger appeal for precision-medicine partnerships and regulatory incentives over time.

Negative Factors

No Revenue & Widening Losses

The absence of operating revenue combined with worsening net losses steadily erodes shareholder capital and necessitates external funding. Structurally, persistent losses limit reinvestment capacity and increase dilution risk until programs either generate revenue or are monetized via deals.

Persistent Negative Cash Flow

Sustained negative operating and free cash flow forces reliance on equity raises or partnerships to finance development. Even with modest burn improvement, ongoing cash consumption constrains strategic optionality, heightens dilution risk, and can delay or downscale clinical plans absent new funding.

Small Team & Execution Risk

A very small headcount increases execution and operational risk for multiple concurrent clinical programs. Reliance on external CROs/partners is likely, which can slow timelines, complicate coordination, and limit in-house capacity to scale development or prepare for commercial activities if trials succeed.

Nuvectis Pharma Business Overview & Revenue Model

Company Description

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.

How the Company Makes Money

Nuvectis Pharma makes money primarily through the development and commercialization of its proprietary cancer therapies. The company's revenue model includes licensing agreements, partnerships with other pharmaceutical companies, and potentially the sale of its products upon receiving regulatory approval. Nuvectis Pharma may also generate income through milestone payments and royalties from its collaborations and partnerships. The company's earnings are significantly influenced by its ability to successfully bring drug candidates to market, navigate complex regulatory environments, and establish strategic alliances with key stakeholders in the healthcare industry.

Nuvectis Pharma Financial Statement Overview

Summary

Income statement and cash flow are weak: no revenue, widening net losses (TTM ~$25.4M vs. ~$19.0M in 2024), and ongoing negative operating/free cash flow (~-$14.5M TTM). The main offset is a stronger balance sheet with no debt and improved equity (~$24.0M TTM), but continued losses keep overall financial performance below average.

Income Statement

NVCT has no revenue across the annual periods provided and in TTM (Trailing-Twelve-Months), while losses are sizable and worsening versus 2024 (TTM net loss of ~$25.4M vs. ~$19.0M in 2024). Operating losses remain deeply negative (TTM EBIT of ~$26.4M), indicating the business is still in a heavy investment/burn phase with no visible operating leverage in the data. Strength is limited to the absence of revenue volatility risk (because revenue is effectively zero), but the primary weakness is persistent and expanding losses.

Balance Sheet

The balance sheet shows no debt in every period presented, which materially reduces financial risk and provides flexibility. Equity has improved from negative levels in 2020–2021 to positive and higher levels more recently (about $24.0M in TTM vs. $9.7M in 2024), supporting a stronger capitalization profile. The key drawback is that returns on equity are very negative in the profitable-capital years (TTM return on equity around -1.51), reflecting ongoing losses that erode shareholder value over time if not reversed.

Cash Flow

Cash generation remains negative, with operating and free cash flow both about -$14.5M in TTM (Trailing-Twelve-Months). Cash burn improved versus 2023 (when operating cash flow was about -$16.0M), and TTM free cash flow growth is shown as positive, but the company is still consistently consuming cash year after year. The main strength is the recent improvement in burn rate, while the main weakness is continued negative free cash flow with no revenue base in the data to offset it.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	-25.81M	-19.00M	-22.90M	-19.23M	-12.89M	-10.00K
Net Income	-25.38M	-19.00M	-22.26M	-19.09M	-12.89M	-10.00K
Balance Sheet
Total Assets	35.59M	18.61M	19.18M	20.41M	6.66M	0.00
Cash, Cash Equivalents and Short-Term Investments	35.44M	18.53M	19.13M	19.99M	5.74M	0.00
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	11.58M	8.89M	6.98M	6.19M	17.66M	10.00K
Stockholders Equity	24.01M	9.71M	12.20M	14.22M	-11.01M	-10.00K
Cash Flow
Free Cash Flow	-14.50M	-12.25M	-15.95M	-13.56M	-9.50M	0.00
Operating Cash Flow	-14.50M	-12.25M	-15.95M	-13.56M	-9.50M	0.00
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	32.77M	11.65M	15.09M	27.81M	15.25M	0.00

Nuvectis Pharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 8.48
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NVCT, the sentiment is Positive. The current price of 8.48 is above the 20-day moving average (MA) of 8.15, above the 50-day MA of 7.11, and above the 200-day MA of 7.52, indicating a bullish trend. The MACD of 0.38 indicates Positive momentum. The RSI at 59.94 is Neutral, neither overbought nor oversold. The STOCH value of 39.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NVCT.

Nuvectis Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NVCT	54 Neutral	$217.21M	-6.43	-158.88%	―	―	-16.26%
OBIO	52 Neutral	$238.28M	―	-166.97%	―	6.46%	-14.32%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NKTX	48 Neutral	$144.90M	-1.47	-26.69%	―	―	25.84%
PYXS	45 Neutral	$109.59M	-1.11	-87.28%	―	-82.53%	-52.00%
MOLN	42 Neutral	$161.13M	-2.20	-49.86%	―	-100.00%	11.02%